Gene expression profiling based identification of CKS1B as a...

Details Gene expression profiling based identification of CKS1B as a... Gene expression profiling based identification of CKS1B as a...

2011-05-03

2011-05-03

Zhou, Shubo (Joe) (Department: 1631)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S006120, C702S019000

Reexamination Certificate

active

07935679

ABSTRACT:
Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifing genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.

Affiliated with

Also associated with

Rating

Gene expression profiling based identification of CKS1B as a... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene expression profiling based identification of CKS1B as a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene expression profiling based identification of CKS1B as a... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2649049